{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:10:39Z","timestamp":1778620239627,"version":"3.51.4"},"reference-count":90,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["2020CXJQ03"],"award-info":[{"award-number":["2020CXJQ03"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000102"],"award-info":[{"award-number":["82000102"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270112"],"award-info":[{"award-number":["82270112"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.cllc.2024.03.005","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T22:56:53Z","timestamp":1710802613000},"page":"215-224.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["ETV6-NTRK2 Fusion in a Patient With Metastatic Pulmonary Atypical Carcinoid Successfully Treated With Entrectinib: A Case Report and Review of the Literature"],"prefix":"10.1016","volume":"25","author":[{"given":"Wusheng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sen","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yilin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunshuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihui","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2024.03.005_bib0001","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/cncr.23542","article-title":"Bronchopulmonary neuroendocrine tumors","volume":"113","author":"Gustafsson","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2024.03.005_bib0002","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/annonc\/mdv041","article-title":"Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids","volume":"26","author":"Caplin","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2024.03.005_bib0003","unstructured":"WHO Classification of Tumours Editorial Board. Thoracic Tumours. 5th ed. Lyon (France): International Agency for Research on Cancer. 2021."},{"key":"10.1016\/j.cllc.2024.03.005_bib0004","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41379-021-00943-2","article-title":"Lung neuroendocrine neoplasms: recent progress and persistent challenges","volume":"35","author":"Rekhtman","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.cllc.2024.03.005_bib0005","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.21037\/tlcr-22-415","article-title":"A multidisciplinary approach to the work up and management of pulmonary carcinoid tumors and DIPNECH: a narrative review","volume":"11","author":"Ramirez","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cllc.2024.03.005_bib0006","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.pulmoe.2022.06.013","article-title":"Large cell neuroendocrine lung carcinoma: a challenging rare tumour","volume":"29","author":"Duarte","year":"2023","journal-title":"Pulmonology"},{"key":"10.1016\/j.cllc.2024.03.005_bib0007","doi-asserted-by":"crossref","first-page":"e6794","DOI":"10.1002\/cam4.6794","article-title":"Prognostic nomogram and epidemiological analysis for lung atypical carcinoid: a SEER database and external validation study","volume":"13","author":"Yi","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.cllc.2024.03.005_bib0008","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lungcan.2021.04.010","article-title":"Long-term survival and recurrence after resection of bronchopulmonary carcinoids: a single-center cohort study of 236 patients","volume":"156","author":"Soldath","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2024.03.005_bib0009","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.3390\/ijms23062916","article-title":"The challenge and opportunity of NTRK inhibitors in non-small cell lung cancer","volume":"23","author":"Qin","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cllc.2024.03.005_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107443","article-title":"ETV6::NTRK3 gene fusion in a patient with metastatic lung atypical carcinoid successfully treated with repotrectinib: a case report","volume":"187","author":"Gao","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2024.03.005_bib0011","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00428-022-03279-7","article-title":"Diagnosis of atypical carcinoid can be made on biopsies\u2009>\u20094 mm2 and is accurate","volume":"480","author":"Reuling","year":"2022","journal-title":"Virchows Arch"},{"key":"10.1016\/j.cllc.2024.03.005_bib0012","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.3390\/cancers14071740","article-title":"Deep learning facilitates distinguishing histologic subtypes of pulmonary neuroendocrine tumors on digital whole-slide images","volume":"14","author":"Ili\u00e9","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cllc.2024.03.005_bib0013","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0151-2022","article-title":"Circulating tumour cells in patients with lung cancer universally indicate poor prognosis","volume":"31","author":"Jin","year":"2022","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.cllc.2024.03.005_bib0014","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3390\/diagnostics12081960","article-title":"Proposal for a new diagnostic histopathological approach in the evaluation of Ki-67 in GEP-NETs","volume":"12","author":"Faviana","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.cllc.2024.03.005_bib0015","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/modpathol.2012.81","article-title":"Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors","volume":"25","author":"Walts","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.cllc.2024.03.005_bib0016","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/his.13096","article-title":"Limited additive value of the Ki-67 proliferative index on patient survival in World Health Organization-classified pulmonary carcinoids","volume":"70","author":"Swarts","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.cllc.2024.03.005_bib0017","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1148\/radiographics.22.2.g02mr01351","article-title":"Bronchial carcinoid tumors of the thorax: spectrum of radiologic findings","volume":"22","author":"Jeung","year":"2002","journal-title":"Radiographics"},{"key":"10.1016\/j.cllc.2024.03.005_bib0018","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s11547-022-01494-5","article-title":"Radiomics in pulmonary neuroendocrine tumours (NETs)","volume":"127","author":"Cozzi","year":"2022","journal-title":"Radiol Med"},{"key":"10.1016\/j.cllc.2024.03.005_bib0019","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.3390\/jcm12113719","article-title":"A systematic review on combined [(18)F]FDG and (68)Ga-SSA PET\/CT in pulmonary carcinoid","volume":"12","author":"Prosperi","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.cllc.2024.03.005_bib0020","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1007\/s00330-022-09326-w","article-title":"The diagnostic and prognostic role of combined [(18)F]FDG and [(68)Ga]-DOTA-peptides PET\/CT in primary pulmonary carcinoids: a multicentric experience","volume":"33","author":"Albano","year":"2023","journal-title":"Eur Radiol"},{"key":"10.1016\/j.cllc.2024.03.005_bib0021","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0280-2021","article-title":"Diagnostic yield and safety of transbronchial lung cryobiopsy and surgical lung biopsy in interstitial lung diseases: a systematic review and meta-analysis","volume":"31","author":"Rodrigues","year":"2022","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.cllc.2024.03.005_bib0022","article-title":"Transbronchial lung cryobiopsy for peripheral pulmonary lesions. A narrative review","author":"Tang","year":"2023","journal-title":"Pulmonology"},{"key":"10.1016\/j.cllc.2024.03.005_bib0023","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.lungcan.2023.02.022","article-title":"Diagnostic efficacy of cryobiopsy for peripheral pulmonary lesions: a propensity score analysis","volume":"178","author":"Furuse","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2024.03.005_bib0024","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0185-2022","article-title":"The role of confocal laser endomicroscopy in pulmonary medicine","volume":"32","author":"Tian","year":"2023","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.cllc.2024.03.005_bib0025","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.7150\/jca.84220","article-title":"Application of bronchoscopy in the diagnosis and treatment of peripheral pulmonary lesions in China: a national cross-sectional study","volume":"14","author":"Huang","year":"2023","journal-title":"J Cancer"},{"key":"10.1016\/j.cllc.2024.03.005_bib0026","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.pulmoe.2020.06.007","article-title":"Bronchoscopic sampling techniques in the era of technological bronchoscopy","volume":"28","author":"Mondoni","year":"2022","journal-title":"Pulmonology"},{"key":"10.1016\/j.cllc.2024.03.005_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1168870","article-title":"Predictive value of the resistance of the probe to pass through the lesion in the diagnosis of peripheral pulmonary lesions using radial probe endobronchial ultrasound with a guide sheath","volume":"13","author":"Hu","year":"2023","journal-title":"Front Oncol"},{"issue":"Suppl 7","key":"10.1016\/j.cllc.2024.03.005_bib0028","doi-asserted-by":"crossref","first-page":"vii120","DOI":"10.1093\/annonc\/mds267","article-title":"Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"\u00d6berg","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2024.03.005_bib0029","doi-asserted-by":"crossref","first-page":"693","DOI":"10.6004\/jnccn.2018.0056","article-title":"NCCN Guidelines insights: Neuroendocrine and Adrenal Tumors, version 2.2018","volume":"16","author":"Shah","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.cllc.2024.03.005_bib0030","first-page":"545","article-title":"Society of Neuroendocrine Neoplasm of China Anti-Cancer Association. China Anti-Cancer Association guideline for diagnosis and treatment of neuroendocrine neoplasm (2022 edition)","volume":"32","year":"2022","journal-title":"Chin Oncol"},{"key":"10.1016\/j.cllc.2024.03.005_bib0031","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2019.11.006","article-title":"The role of surgery for atypical bronchopulmonary carcinoid tumor: development and validation of a model based on surveillance, epidemiology, and end results (SEER) database","volume":"139","author":"Chen","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2024.03.005_bib0032","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s40520-022-02112-0","article-title":"Long-term survival analysis of sublobar resection versus lobectomy for older patients with early-stage pulmonary carcinoid tumour: a database-based propensity score-matched study","volume":"34","author":"Yang","year":"2022","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.cllc.2024.03.005_bib0033","first-page":"921","article-title":"A national study of surgically managed atypical pulmonary carcinoid tumors","volume":"112","author":"Walters","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2024.03.005_bib0034","doi-asserted-by":"crossref","first-page":"e991","DOI":"10.1097\/SLA.0000000000004593","article-title":"Sublobar resection versus lobectomy for early-stage pulmonary carcinoid tumors \u22643 cm in size: a SEER population-based study","volume":"276","author":"Xu","year":"2022","journal-title":"Ann Surg"},{"key":"10.1016\/j.cllc.2024.03.005_bib0035","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0115-2020","article-title":"Bronchoscopic diagnosis and treatment of endobronchial carcinoid: case report and review of the literature","volume":"30","author":"Papaporfyriou","year":"2021","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.cllc.2024.03.005_bib0036","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cllc.2020.12.004","article-title":"Recent advances in the management of typical and atypical lung carcinoids","volume":"22","author":"Prinzi","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2024.03.005_bib0037","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.3390\/jcm12165337","article-title":"Advances in endoscopic management of endobronchial carcinoid","volume":"12","author":"Messina","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.cllc.2024.03.005_bib0038","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/JTO.0b013e3181861d7b","article-title":"Proceedings of the IASLC international workshop on advances in pulmonary neuroendocrine tumors 2007","volume":"3","author":"Lim","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2024.03.005_bib0039","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1210\/jc.2011-2088","article-title":"Clinical review: current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy","volume":"97","author":"Bousquet","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.cllc.2024.03.005_bib0040","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S1010-7940(02)00055-6","article-title":"Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide","volume":"21","author":"Filosso","year":"2002","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.cllc.2024.03.005_bib0041","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.669484","article-title":"Outcome of patients with metastatic lung neuroendocrine tumors submitted to first line monotherapy with somatostatin analogs","volume":"12","author":"Lenotti","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.cllc.2024.03.005_bib0042","doi-asserted-by":"crossref","first-page":"S906","DOI":"10.1016\/j.annonc.2021.08.178","article-title":"1096O Lanreotide autogel\/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): results from the phase III SPINET study","volume":"32","author":"Baudin","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2024.03.005_bib0043","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1007\/s00259-015-3262-8","article-title":"Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET","volume":"43","author":"Ianniello","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cllc.2024.03.005_bib0044","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00259-015-3190-7","article-title":"Long-term results of PRRT in advanced bronchopulmonary carcinoid","volume":"43","author":"Mariniello A","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cllc.2024.03.005_bib0045","unstructured":"Food and Drug Administration. Highlights of Prescribing Information. Accessed: March 4, 2024. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/208700s000lbl.pdf."},{"key":"10.1016\/j.cllc.2024.03.005_bib0046","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2024.03.005_bib0047","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2024.03.005_bib0048","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/S1470-2045(17)30681-2","article-title":"Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial","volume":"18","author":"Ferolla","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2024.03.005_bib0049","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.3390\/cancers14194730","article-title":"Survival benefit of adjuvant chemotherapy in pulmonary carcinoid tumors","volume":"14","author":"Sobash","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cllc.2024.03.005_bib0050","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0174-2022","article-title":"Rare thoracic cancers: a comprehensive overview of diagnosis and management of small cell lung cancer, malignant pleural mesothelioma and thymic epithelial tumours","volume":"32","author":"Dumoulin","year":"2023","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.cllc.2024.03.005_bib0051","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.pulmoe.2022.11.008","article-title":"Unresectable stage III non-small cell lung cancer: insights from a Portuguese expert panel","volume":"30","author":"Ara\u00fajo","year":"2024","journal-title":"Pulmonology"},{"key":"10.1016\/j.cllc.2024.03.005_bib0052","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.lungcan.2017.03.006","article-title":"PD-L1 expression in neuroendocrine tumors of the lung","volume":"108","author":"Tsuruoka","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2024.03.005_bib0053","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1530\/EC-19-0308","article-title":"PD-1 and PD-L1 expression in pulmonary carcinoid tumors and their association to tumor spread","volume":"8","author":"Vesterinen","year":"2019","journal-title":"Endocr Connect"},{"key":"10.1016\/j.cllc.2024.03.005_bib0054","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1038\/s41467-023-38611-5","article-title":"Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin","volume":"14","author":"Capdevila","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.cllc.2024.03.005_bib0055","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejca.2022.03.029","article-title":"Avelumab in unresectable\/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): combined results from NET-001 and NET-002 trials","volume":"169","author":"Chan","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2024.03.005_bib0056","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1158\/1078-0432.CCR-22-1552","article-title":"A phase II clinical trial of nivolumab and temozolomide for neuroendocrine neoplasms","volume":"29","author":"Owen","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2024.03.005_bib0057","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1001\/jama.2019.3241","article-title":"Association of patient characteristics and tumor genomics with clinical outcomes among patients with non\u2013small cell lung cancer using a clinicogenomic database","volume":"321","author":"Singal","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.cllc.2024.03.005_bib0058","doi-asserted-by":"crossref","DOI":"10.1177\/17534666211066064","article-title":"KRAS and MET in non-small-cell lung cancer: two of the new kids on the \u2018drivers\u2019 block","volume":"16","author":"Garcia-Robledo","year":"2022","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.cllc.2024.03.005_bib0059","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.pulmoe.2022.11.009","article-title":"Improving non-small-cell lung cancer survival through molecular characterization: perspective of a multidisciplinary expert panel","volume":"30","author":"Fernandes","year":"2024","journal-title":"Pulmonology"},{"key":"10.1016\/j.cllc.2024.03.005_bib0060","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1038\/ncomms4518","article-title":"Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids","volume":"5","author":"Fernandez-Cuesta","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.cllc.2024.03.005_bib0061","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40169-019-0238-5","article-title":"Systemic treatment for lung carcinoids: from bench to bedside","volume":"8","author":"Torniai","year":"2019","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.cllc.2024.03.005_bib0062","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41379-018-0118-3","article-title":"Molecular characterization of cancers with NTRK gene fusions","volume":"32","author":"Gatalica","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.cllc.2024.03.005_bib0063","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920975613","article-title":"A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors","volume":"12","author":"Forsythe","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.cllc.2024.03.005_bib0064","article-title":"NTRK fusion in non-small cell lung cancer: diagnosis, therapy, and TRK inhibitor resistance","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.cllc.2024.03.005_bib0065","article-title":"Response to icotinib plus chemotherapy in pulmonary atypical carcinoid harboring the EGFR L858R mutation: a brief report","volume":"2","author":"Chen","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.cllc.2024.03.005_bib0066","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1097\/JTO.0000000000000635","article-title":"A case of atypical carcinoid: harboring variant 3a\/b EML4-ALK rearrangement","volume":"10","author":"Fukuizumi","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2024.03.005_bib0067","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.21037\/tlcr-22-394","article-title":"Metastatic pulmonary carcinoids with EML4-ALK fusion response to ALK inhibitors: two case reports and review of literature","volume":"11","author":"Lei","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cllc.2024.03.005_bib0068","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1093\/annonc\/mdv252","article-title":"Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)","volume":"26","author":"Grande","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2024.03.005_bib0069","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.2007.13.6374","article-title":"Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.03.005_bib0070","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3109\/07357907.2016.1174257","article-title":"A phase II study of the combination of bevacizumab, pertuzumab, and octreotide LAR for patients with advanced neuroendocrine cancers","volume":"34","author":"Bendell","year":"2016","journal-title":"Cancer Invest"},{"key":"10.1016\/j.cllc.2024.03.005_bib0071","article-title":"Clinicopathologic features of non-small-cell lung cancer harboring an NTRK gene fusion","volume":"2018","author":"Farago","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.cllc.2024.03.005_bib0072","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3892\/mco.2014.318","article-title":"Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451 in vitro","volume":"2","author":"Tatematsu","year":"2014","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.cllc.2024.03.005_bib0073","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.cllc.2019.09.004","article-title":"Evidence of NTRK1 fusion as resistance mechanism to EGFR TKI in EGFR+ NSCLC: results from a large-scale survey of NTRK1 fusions in Chinese patients with lung cancer","volume":"21","author":"Xia","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2024.03.005_bib0074","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41379-019-0324-7","article-title":"NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls","volume":"33","author":"Solomon","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.cllc.2024.03.005_bib0075","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41698-023-00427-3","article-title":"Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in China","volume":"7","author":"Xu","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.cllc.2024.03.005_bib0076","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/JTO.0000000000000419","article-title":"Atypical carcinoid tumor of the lung: a surveillance, epidemiology, and end results database analysis","volume":"10","author":"Steuer","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2024.03.005_bib0077","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors","volume":"28","author":"Demetri","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2024.03.005_bib0078","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2024.03.005_bib0079","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1093\/neuonc\/noab101","article-title":"Epidemiology of brain metastases and leptomeningeal disease","volume":"23","author":"Lamba","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.cllc.2024.03.005_bib0080","article-title":"Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer","volume":"188","author":"Cho","year":"2023","journal-title":"Lung cancer"},{"key":"10.1016\/j.cllc.2024.03.005_bib0081","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1200\/JCO.2021.39.15_suppl.3108","article-title":"Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer","volume":"39","author":"Hong","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.03.005_bib0082","article-title":"Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion-positive lung cancers","volume":"6","author":"Drilon","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.cllc.2024.03.005_bib0083","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/neuonc\/noab274","article-title":"Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors","volume":"24","author":"Doz","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.cllc.2024.03.005_bib0084","article-title":"Larotrectinib demonstrates CNS efficacy in TRK fusion-positive solid tumors","volume":"3","author":"Rosen","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.cllc.2024.03.005_bib0085","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/ccr3.3900","article-title":"Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6-NTRK3 gene fusion","volume":"9","author":"Pitoia","year":"2021","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.cllc.2024.03.005_bib0086","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s40265-021-01503-3","article-title":"Entrectinib: a review in NTRK+ solid tumours and ROS1+ NSCLC","volume":"81","author":"Frampton","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.cllc.2024.03.005_bib0087","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2217\/fon-2019-0534","article-title":"Systematic review of neurotrophic tropomyosin-related kinase inhibition as a tumor-agnostic management strategy","volume":"16","author":"Chu","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.cllc.2024.03.005_bib0088","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2024.03.005_bib0089","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/s41591-019-0542-z","article-title":"Resistance to TRK inhibition mediated by convergent MAPK pathway activation","volume":"25","author":"Cocco","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.cllc.2024.03.005_bib0090","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/2159-8290.CD-17-0507","article-title":"A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730424000408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730424000408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:09:12Z","timestamp":1778616552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730424000408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":90,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1525730424000408"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2024.03.005","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ETV6-NTRK2 Fusion in a Patient With Metastatic Pulmonary Atypical Carcinoid Successfully Treated With Entrectinib: A Case Report and Review of the Literature","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2024.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}